MedTrace Logo

Cardiovascular Risk Factors and LCH in Adults

NCT00483925 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2007-06-08

No results posted yet for this study

Summary

Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation and hypopituitarism, conditions associated with increased risk of cardiovascular diseases.

Objective: To investigate glucose and lipid metabolism, insulin resistance, structural arterial and functional endothelial properties in patients with multisystem LCH in a prospective, observational study.

Interventions:Cardiovascular risk factors: arterial blood pressure, lipid profile, mathematical indices of insulin resistance (IR), intima media thickness, brachial artery flow mediated dilatation, dynamic indices of IR, pituitary function and C-reactive protein will be estimated in patients with LCH and in a control group matched for gender, age, BMI and smoking habits.

Conditions

  • Histiocytosis, Langerhans-Cell

Sponsors & Collaborators

  • Laikο General Hospital, Athens

    lead OTHER

Principal Investigators

  • Gregory Kaltsas, MD, FRCP · Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483925 on ClinicalTrials.gov